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Clinical Leadership Theme
In accordance with the American Association College of Nursing (AACN) End-ofProgram Competencies (2013), this project encompasses the curriculum element of Nursing
Leadership: Advocate. This relates to the project in terms of using evidence-based practice
(EBP) to increase vaccination rates within a community clinic, thereby working to change
practice and improving client healthcare outcomes both within the short-and long-term time
frame. The overall Improvement Theme for this project is to utilize known factors associated
with lack of human papillomavirus (HPV) vaccination compliance, and implement interventions
to improve vaccination rates and compliance.
Statement of the Problem
During an organizational-wide Quality Improvement meeting earlier this year it was
noted that as a whole, completion of 3-dose HPV vaccinations were extremely low. At this
particular clinic it was noted that for females, ages 11-26, only 7% had completed the 3-dose
series. The remaining 93% encompasses all those individuals that have not received either the
1st, 2nd, or 3rd dose. While any number of contributing factors can be attributed to these rates,
several have been found to be more prominent at this clinic. By identifying known barriers in
reduced compliance, and implementing interventions, the aim is to increase overall vaccination
compliance rates, while also increasing education in areas of patient concerns that would
otherwise serve as deterrents to them receiving the vaccine.
Project Overview
The goal of this project is to have patients return for their 2nd or 3rd dose of the HPV
Gardasil ® 9 vaccine, thereby increasing compliance rates at the clinic. The intervention
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implemented was a follow-up reminder phone call, to serve as a reminder for the patient to return
for their 2nd or 3rd dose. This directly relates to the Global Aim Statement that is to improve the
rate of HPV vaccination continuing compliance within the female population of the community
clinic. The goal of this project is that in introducing the intervention, via a follow-up phone call,
we will not only increase vaccination compliance rates but will also be able to provide education
regarding the HPV vaccine. Recent figures show that our clinic serves ~2,375 female patients
between the ages of 11-26, the age during which all 3 doses of the Gardasil ® 9 should be
administered. However of that count only 166 individuals completed the 3-dose vaccination,
equal to only 7%. For the purposes of this project, the focus will be in contacting those
individuals who have already received the 1st or 2nd dose. The aim is to enable individuals to
return for their 2nd or 3rd dose, thereby increasing vaccination compliance or completion of the 3dose series.
Rationale
In analyzing the microsystem and current policies/protocols, several needs become
apparent. Refer to Appendices: (A) for the Fish-Bone Diagram, (B) for the Process Map
flowchart, (C) for the SWOT analysis, (D) Cost Analysis, (E) for the Stakeholder Analysis, and
(F) for the PDSA ramps. These analyses were done to obtain a more detailed perspective into
the microsystem and therefore the project analysis.
Root-Cause Analysis
In performing the microsystem assessment, the use of the fish-bone diagram highlighted
multiple areas of concern regarding patients, clinic staff, environment, equipment, methods, and
materials. Current vaccination policy did not delineate scheduling the 2 month (2nd dose) and 6
month (3rd dose) vaccinations. Related to this factor, there were also no reminder cards/magnets
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that patients could take home with them. Third, there was no standing order for vaccination
follow-ups, such as a reminder via e-mail, text message, phone call, or letter if the patient had
not returned for the next dose within an allotted time period. Related to this factor, there were
also no electronic medical record (EMR) alerts in the computerized charting system. In
reviewing available educational information at the clinic, there were also no pamphlets,
educational flyers, or posters that highlight HPV awareness in patient care rooms.
As mentioned earlier, the goal of this project was to improve the rate of HPV vaccination
compliance within the female population of the community clinic. Education and awareness was
crucial in implementing this process, whether about the actual vaccine or financial assistance
available. An example of this was that for those individuals under the age of 18, the State of
California operates the Vaccines for Children (VFC) program, which provides vaccinations at no
cost, and is a program that is offered at our clinic (CDC, VFC Program). Thereby the
intervention of follow-up call is two-fold in that (a) we schedule 2nd or 3rd dose vaccinations
and increase compliance rates, and (b) provide HPV vaccination education to eliminate possible
deterrents.
Process Map
The use of a flow chart was beneficial as it highlighted areas of missed opportunities by
clinic staff. In total there were five missed opportunities found during a patient visit. The
purpose of using a flowchart for office visits was to highlight the need for not only missed
opportunities but also to show where interventions could take place. Missed opportunities were
one of the most significant deterrents found in the President’s Cancer Panel Annual Report of
2012-2013, the Centers for Disease Control and Prevention (CDC), the Advisory Committee on
Immunization Practices (ACIP), and the National Vaccine Advisory Committee (NVAC). These
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organizations all suggest that missed clinical opportunities are the most important reason or
deterrent why HPV vaccination rates are the so low in the United States. It is important to note
that while vaccinations need to be checked by licensed providers; MAs may provide pamphlets
or handouts, and RNs and MDs can discuss and provide education regarding any concerns of the
vaccination. The important take-away from this flowchart is that at any point of the office visit,
the HPV vaccination discussion can be initiated and any questions may then be addressed or
directed to the correct personnel.
SWOT Analysis
The use of a SWOT analysis was useful to better acquaint myself with the issues that our
specific clinic faces, as well as those issues that could be addressed organization-wide. One of
the most encouraging strengths found was that the low rates of HPV vaccination were a concern
not only for our clinic, but other organization clinics. To this end the Director of Population
Health was working to secure a grant to address this issue, which I will revisit in the Results
section of this project. Other strengths included the use of public/private assistance programs to
help pay for the cost of the vaccine. One of the other important strengths identified is that due to
the amount of patients we see there is a MA strictly assigned to immunizations, thereby we can
schedule patients in on a relatively short basis for immunization appointments.
Some of the weaknesses found during this analysis involved the identification of barriers
such as low staff compliance and accountability, checks & balances (i.e. flags in EHR, weekly
reports and meetings to educate staff on the need for patient education and f/u appointment
scheduling), and actual time spent training staff on how to initiate the discussion. Other
weaknesses included no current policy regarding the scheduling of 2nd or 3rd doses of any
vaccine requiring more than one dose, and no policy regarding follow-up reminders.
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Understanding weaknesses allows us to look for opportunities in our external realm.
Some of the areas found were education and alerts. This affects all clinical staff whether front
office, MAs, RNs, MDs, or NPs. As the organization uses EHRs, they were currently pursuing
the capability to create alerts when the patient’s chart was activated. An example of this would
be that the patient calls to schedule a visit, and an alert signals the personnel that they are due for
their 1st, 2nd, or 3rd dose of the HPV vaccine, at that time the person attending to the patient can
inquire and schedule them for the vaccine. Another opportunity was to actually create a policy
regarding scheduling of subsequent visits and the use follow-up reminders via phone call or
letter. The use of text messaging had been previously used for other projects, but patients did not
like these reminders and would usually opt out of this feature.
As with any project there are threats to the immediate, continued, and future success of
the project. One of the two main threats is staff compliance, whether it is in regards to missed
opportunities, education, or inquiring of the vaccine. The other main threat is that of the patients,
in that despite all effort they still do not come in for subsequent doses, thereby decreasing
compliance and increasing risk for HPV-associated infections and cancers in the future. One of
the most important ways to mitigate these threats is education for both patients and clinic staff.
In particular if the staff is made aware of current statistics, ways to improve compliance rates,
educated on importance of HPV vaccinations, and how to implement these interventions, they
will be more likely to comply themselves. As a CNL it is important to gather data, analyze and
make sense of it, and apply evidence-based practice (EBP) for improving facility protocols and
patient outcomes.
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Cost-Analysis and Stakeholder Analysis
Currently the manufacturer (Merck) of Gardasil ® 9 charges $263 per dose (or what the
clinic terms private stock). VFC does not charge for the vaccines they send the clinic, and the
patients that are 11-18 years of age receive the vaccine at no cost. If the patient is 19-20 years of
age, Medicaid covers the cost via the Early and Periodic Screening, Diagnostic, and Treatment
benefit (President’s Cancer Panel Annual Report, Goal 3, Objective 3.3). If the individual falls
between the ages of 21-26 and demonstrates financial need, they may obtain the vaccine free of
charge through the Merck Vaccine Patient Assistance Program (MVPAP). However the
application form needs to be filled out for each dose and the clinic has seen a reduced effort from
patients in regards to this form, therefore reduced compliance. If the individual in question does
not fall within these categories the clinic offers the vaccine at $175 per dose, plus a sliding scale
administration fee based on income and/or insurance.
Understanding the safety, efficacy, and importance of the HPV vaccination is crucial to
identifying stakeholders within this project and its continued and future success. In addition it is
also important to be aware of the complications that may arise from not receiving the
vaccination, as this information can help in influencing the reception and acceptance of the
vaccination, leading to increased compliance. For this project, the most important stakeholder is
the patient as they will be the ones directly affected. Also equally important are
parents/caregivers, especially for those individuals that are 11-18 years of age and are ultimately
the deciding factor at this age. Providers are also crucially important in introducing this
discussion during annual visits or otherwise. MAs are important because they are often the link
between patients and healthcare providers. RNs are important as they will be doing the bulk of
education and follow-up needed to ensure compliance. If these stakeholders can align together
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for the good of the patient, we will see increased compliance at the clinic, and optimistically a
decreased risk of HPV-associated infections and cancers in the future.
Methodology
As mentioned earlier, during the organizational Quality Improvement, it was found that
the clinic serves ~2, 375 females, ages 11-26. Of this amount it was found that roughly 7% or
~166 patients had received all 3 doses of the Gardasil ® 9 vaccination for HPV prevention. In
the President’s Cancer Panel Annual Report (2013) the need to increase HPV vaccination rates
was the primary goal in preventing various types of future cancers and other HPV-related
infections/diseases (Executive Summary, para. 1). Furthermore a Healthy People 2020 goal
(2013) is to have 80% of adolescent females, ages 13-15, to have received the full 3-dose series
(About the Data, Target).
The objective of this project was to increase compliance by implementation of follow-up
phone calls for those individuals who still needed their 2nd and/or 3rd doses. The phone call
would allow for follow-up questions, provision of education, scheduling appointment for next
dose, and anticipating or eliminating any future deterrents for not complying with the
vaccinations. In addition the clinic now offers Gardasil ® 9 future appointment cards where MAs
can schedule the dates of the subsequent doses, when individuals receive their 1st dose. As a
result MA education is also an important facet of implementation to ensure compliance not only
for the duration of the project but in the continued success of these interventions. The use of
Lewin’s Change Theory has been especially beneficial in not only creating awareness but in
providing education as to the why. This theory encompasses the use of 3 components:
unfreezing, change, and refreezing (Nursing Theory, Lewin’s Change Theory, para. 4). Bowers
(2011) likens this theory to the “processes of planning, implementing and evaluating care” and
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that “if behavioral resistance is not identified and worked with, they can reverse even the bestintended change projects” (p. 20, 21). Thereby using the theory has allowed for staff buy-in to
help ensure interventions are successful now and in the future.
Lewin’s Change Theory

UNFREEZING

•
•
•
•

Generate awareness
Increase patient education
Highlight missed opportunities
Ensure non-judgemental
environment for staff to voice
concerns, thoughts, and ideas

MOVING

• Barriers identified...
• not scheduling subsequent appointments
• not providing patients/families with education
materials
• no f/u to ensure compliance
• Intervention of EBP: f/u phone call

REFREEZING

• Reinforcement of new
behaviors and actions
• Scheduling next dose
vaccination appointments
• Ensuring f/u via phone
call

Education is difficult to measure; therefore the data used to measure effectiveness of
interventions is data pertaining to whether or not individuals came in for subsequent doses after
intervention of the follow-up phone call. The desired outcome is to see a 10% increase overall
within the 2nd and 3rd doses. To ascertain whether the said interventions have been successful,
we will measure the 2nd and 3rd dose rates, over an 8-week period. These goals are such
because as patient records are examined, it is unsure how many individuals will fall within the 8week time constraint for the project.
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Data Source/Literature Review

The site for this project is a private, non-profit 501(c)(3) community health organization
clinic, providing medical, dental and behavioral health care to residents of Riverside County,
located in Southern California. This clinic serves a very racially diverse community, from
newborns to geriatrics, and at this particular site a Women’s Health, Behavioral Health, and
Pediatrics team. The clinic staff includes MDs, NPs, PAs, RNs, MAs, lab technicians,
phlebotomists, and an abundance of ancillary office staff. As a community clinic the main focus
of care is preventative, and how we can keep the community healthy by providing care to those
not insured, or whose insurance will not cover services at other healthcare locations. At the
community health level, vaccinations are a fundamental part of preventative healthcare and
subsequent population/community health. As we serve a large adolescent/young adult
population, the need for immunizations is a large component of their healthcare.
The process of finding relevant literature took some time as there is a plethora of
information regarding the importance of HPV vaccination and continued compliance to reduce
HPV-related infections and cancers. To be more effective and selective in literature research the
use of PICO served to narrow the focus and to garner specific information. The following were
the PICO search terms:
P: HPV vaccination compliance in the female population using EBP follow-up
I: EBP follow-up methods: phone call, Gardasil® cards
C: no follow-up and effects on compliance
O: follow-up leads to increased compliance
Overall I was able to find a good amount of content to support my project, being that this is a
current national priority. The importance of introductory and continued HPV vaccination
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compliance is a priority mentioned in both the President’s Cancer Panel Annual Report (2013)
and the Healthy People 2020 goals.
The HPV vaccination and importance of compliance in receiving all 3 doses has been
researched time and time again. Much of the literature is geared towards ways to increase
compliance, importance of receiving vaccine prior to sexual activity, studies showing that
without vaccinations there are increases in HPV-infections and cancers. Highlighting the
importance of HPV vaccination is the President’s Cancer Panel Annual Report (2013) in that just
two viruses, HPV16 and HPV18 are responsible for more than “22,000 cancers in the United
States…Yet, in the U.S., only one-third of adolescent girls” are receiving the vaccine (The Case
for HPV Vaccination, para. 2). Furthermore the researchers behind this report state that there are
ways increase introductory HPV vaccinations and compliance by (1) reducing missed clinical
opportunities to recommend and administer vaccines, (2) increase parents’, caregivers’, and
adolescents’ acceptance of HPV vaccines, and (3) maximize access to HPV vaccination services
(President’s Cancer Panel Annual Report, How to Accelerate HPV Vaccine Uptake in the U.S.).
This literature was particularly useful in looking for missed opportunities when the Process
Mapping Flow-Chart was being done, and to that extent there were five missed opportunities
found.
Another piece of literature that provided information necessary to understand deterrents
that were a part of the parent or caregiver decision to not vaccinate came from the Centers for
Disease Control and Prevention (CDC) (2013) Morbidity and Mortality Weekly Report
(MMWR) on the HPV coverage among adolescent girls. This report found that there were five
leading factors regarding vaccination declination: (1) it was not needed, (2) it was not
recommended, (3) there were vaccination safety concerns, (4) there was a lack of knowledge
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about the vaccine and/or disease, and (5) the individual was not sexually active. In addition the
report also echoed the findings of the President’s Cancer Panel Annual Report, in that in just the
span of six years missed opportunities increased by 63.2%, and if these missed opportunities had
been eliminated there would have been a compliance rate of 92.6% (Vaccination Coverage, para.
3). This highlights the importance of not only providing education but increasing awareness of
not only the vaccination but possible future implications if not received.
Focusing on missed opportunities the National Vaccine Advisory Committee (NVAC)
(2013) outlined a Summary of Standards to address shortcoming from missed opportunities
including the following:
“(1) ensure professional competencies in immunizations, (2) assess immunization status
in every patient care and counseling encounter and strongly recommend needed
vaccine(s), (3) ensure that receipt of vaccination is documented in patient medical record
and immunization registry, (4) incorporate immunization needs assessment into every
clinical encounter, (5) stay up-to-date on, and educate patients about, vaccine
recommendations, and (6) implement systems to incorporate vaccine assessment into
routine clinical care…” (p. 3, 4)
In particular the use of implementing systems is something that the organizational IT department
is currently working on for other programs, but it would be something useful for maintaining
vaccinations up-to-date and reminder systems.
Focusing on deterrents to receiving vaccinations, Saraiya, Steben, Watson, and
Markowitz (2013) found that the highest precursors to denial of vaccination were the factors of
finances, vaccination acceptability, how or where the patient would receive the vaccination, and
whether or not the provider recommended the vaccination. This had to do with the provider-
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patient relationship, which also highlights the need for not missing those opportunities to have
the HPV vaccination discussion. The researchers also stated that although the HPV vaccinations
are costly now (HPV is one of the most expensive vaccines out at this moment), the benefit is
that it may ultimately reduce cancers, which in turn may reduce morbidity and treatment costs
associated with HPV-related infections and/or cancers.
In relation to reducing cancers, an article by Cox, Cox, Sturm, and Zimet (2010) stated
that HPV vaccinations were of such importance within the minority/disadvantaged community,
because it will often be these populations that will not have access to routine Pap screenings for
cancer. This was an astounding correlation and all the more relevant for the clinic as we serve a
largely Hispanic but increasingly immigrant community from the Middle East, Central and South
America, and Africa. This research brought forth an important issue that until I had read the
research, had not previously thought about and its implications for the community clinic setting.
All of the above literature is important to understand before implementing EBP
interventions. The choice of follow-up phone call reminder was based upon literature
showcasing that EBP reminder/recall for immunizations was very effective in increasing
compliance (Suh, Saville, Daley, Glazner, Barrow, Stokley, Dong, Beaty, Dickinson, & Kempe,
2013). In this particular study, researchers used both letters and phone calls as reminder and
focused only on those individuals who had already received the 1st dose of HPV. At the end of
their study it was found that there was an 11.2% increase in compliance. This research showed
that the use of EBP practice, follow-up reminder phone call, was successful and effective in
increasing HPV compliance rates.
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Timeline

This project began towards the end of August 2015 and was completed late-November
2015. The biggest delay was in obtaining the list of patients that had already received the 1st or
2nd dose, because it was the foundation upon which the project would proceed. Another delay
was in receiving a response from the organization Finance Department regarding the finances of
the vaccine also took a little more time than expected. Refer to Appendix G for the Timeline of
this project.
Expected Results
The proposed goal of a combined 10% increase in both 2nd and 3rd doses amounts to ~23
individuals. The list of patients showed that there are ~ 172 females who had received the 1st
dose, and 81 females who had received the 2nd dose. The aim of a 10% increase was to be able
to present at a Quality Improvement meeting, the usefulness of a Clinical Nurse Leader, and
what we can achieve. More specifically I wanted to present to the organization that the use of
EBP is not only something used in hospitals, but is something that can be used in any
microsystem. Being able to show how a simple EBP method of a follow-up reminder phone call
(although it does take time), and providing patient education during that time, can increase
patient compliance which then directly improves clinic and possibly organization-wide statistics.
As the project progressed, it was important to remain flexible in what to expect, what
changes to make, and trying to foresee any issues that could have arisen, thereby avoiding
delays. To that extent, the use of various types of analysis, including the SWOT and Fish-Bone
Diagram, have been especially useful in delineating areas of concern, and what could cause those
delays. Although one of the possible “delays” identified had to do with staff compliance, as one
does not know how they will react to change, I have been pleasantly surprised. Although there is
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high MA turnover, the staff that has longevity has shown such pride in what they do, how they
do it, the care they provide to their patients, and really take ownership of their actions. I have
also found that staff acceptance and buy-in is more effective not only if they have a say, but if
they are provided with the education behind the changes. For me personally, hearing that “Oh,
now I understand or I see…” and seeing that “light-bulb” moment of recognition and
understanding has been such a motivating experience to push forward. It also highlights the
importance and significance of what a CNL can do within any setting.
Evaluation
The project resulted in a 26.7% increase in 2nd dose compliance, and 31.6% increase in
3rd dose compliance. Overall there was a combined increase of 27.9%, surpassing the original
goal of 10%. While the work was very tedious, having these results clearly shows that EBP
follow-up phone call reminders are successful in increasing HPV compliance rates.
Midway through this project we were informed that our clinic had received a sizable
grant from the Centers of Disease Control and Prevention (CDC) in conjunction with the
American Cancer Society (ACS). This was a major grant as our clinic was 1 in 10 chosen
nationwide to receive this grant, for the sole purpose of increasing HPV vaccination compliance
rates. As such I was able to present with the ACS representative and the Director of Population
Health, how the grant would affect our services, and what was hoped to be achieved by use of
this grant. As of now we have been able to place alerts on the EHR system, and order pamphlets
and educational materials. The goal for the clinic in regards to this grant is to see an overall
increase of 15% by the middle of 2016.
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Nursing Relevance

The most significant contribution of increasing HPV vaccination compliance is
something whose full impact and implications will not be recognized until later. The mentality
of intervening upstream rather than downstream is exactly what this project entails. Throughout
the literature research, time spent with the project, educating staff and patients, the ultimate goal
is to prevent future cases of HPV-associated infections and cancers. The CDC (2012) estimates
that there are approximately 79 million (male and female combined in the U.S) currently infected
with 1 of 40 types of HPV. Furthermore they estimate that there are approximately 14 million
new infections every year in the United States alone. These are astounding and even more so
when we realize that a simple 3-dose vaccination can prevent the majority of these infections.
While most of the 40 types of HPV are not cancerous, there are certain types that can cause
cancers of the “cervix, anus, penis, vulva, vagina, and oropharynx (back of throat including base
of tongue and tonsils)…genital warts and, rarely, respiratory tract warts in children” (CDC, HPV
Background). In addition to that there are approximately “11,000 women diagnosed with
cervical cancer and about 4,400 women die from this disease in the U.S. each year” (CDC, HPV
Background). While all most likely could not have been prevented, the majority could have been
most likely prevented by vaccination.
There is no present way to estimate how many infections or cancers can be prevented by
the vaccination. However by providing education to both staff and patients, implementing EBP
interventions, and getting this population to vaccinate, the future implications are too vast to not
acknowledge and act now.
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Summary Report

The overall goal of this project was to increase HPV 2nd and 3rd dose compliance rates by
a combined 10% among the female adolescent population (ages 11-26). This was to be achieved
by implementing EBP follow-up calls to not only schedule appointments but also to serve as a
reminder for patients to come into previously scheduled appointments. This project was chosen
as prior clinic and organization-wide meetings had delineated compliance rates at just 7%,
thereby highlighting the importance of attention needed to this area. As mentioned above the
population targeted was female adolescents, ages 11-26. This population was via a community
health clinic, where vaccinations are a primary component of preventative healthcare.
There were various methods employed to implement this project including an initial
microsystem assessment, which entails a Root Cause Analysis (Fish-Bone Diagram), Process
Mapping (Flow Chart), SWOT analysis, Cost-Analysis, Stakeholder Analysis, and PDSA ramps.
In addition maintaining a schedule by use of timeline was also imperative in ensuring that the
above microsystem assessment and actual implementation of project would occur in a timely
manner. Mid-way through the project the clinic received a substantial CDC grant (in association
with ACS), to specifically work on increasing HPV compliance rates overall, including the male
and female population by the middle of next year. Although my personal project was focused on
the female population, the grant was helpful in creating EHR alerts when the patient chart is
accessed, providing educational materials for clinic staff and patients alike, and in creating a
larger discussion and imperative for change.
As mentioned above the goal was for a combined increase of 10%. Using a compiled list
of patients that was received from the Director of Population Health, showed the potential
possibilities as there were 172 individuals who needed the 2nd dose, and 57 individuals who
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needed the 3rd dose. Therefore there were a total of 229 individuals, and the proposed goal of
10% indicated a need to have at minimum 23 patients to receive their next dose. Overall the
project surpassed its goal as we were able to have 46 2nd dose and 18 3rd dose individuals receive
their next dose. With these results there was a combined increase in compliance of 27.9%,
which exceeded the original 10% goal.
Sustainability of this project is largely dependent on the front-line office staff, which
includes everyone from the operators to physicians, and the Patient Care Coordinators who focus
on doing follow-up for a number of projects that are simultaneously on-going. There is a clear
responsibility and role for each individual in initiating the HPV discussion, directing to the
proper resources/personnel, and ensuring follow-up via a variety of ways. Throughout this
practicum it was crucially important to not only the introductory, but continued and future
success of the project to educate clinic staff. In educating, we empower and allow them to be
proactive, take ownership and pride in how we can change patient outcomes as a team.
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Appendix A:
Root Cause Analysis: Fish-Bone Diagram
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Appendix B:
Process Map: Flow Chart
Greeted:

MO #1

Arrival for Visit

-front office staff does not ask if
any additional concerns for
visit today

PATIENT ROOM: MAs

Patient Room: Waiting

MO #3

MO #2

-Do not ask if any additional
concerns?
-Do not review vaccines in
EMAR if visit is not for
vaccinations

-No HPV pamphlets available in
patient rooms
-No HPV posters on patient
room walls

Patient Room: RNs or MDs

Patient Room: MAs

MO #4

MO #5

-Do not initiate discussion or
provide education
-If HPV vaccine received, do not
discuss importance of
compliance

-Do not ask if any additional
questions/concerns?
-If either 1st or 2nd HPV vaccine
received, do not schedule
subsequent doses

PATIENT LEAVES
OFFICE

5 missed

and there are a total of
opportunities!

*MO = Missed Opportunity
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Appendix C:
SWOT Analysis

• support from upper level
management to improve
vaccination rates
• use of Immunization MA
• organization is actively
pursuing and researching the
possibility of federal
grants/funding.
• the clinic uses other private
and public programs to assist
with cost:
• VFC program
• Medicaid Early and Periodic
Screening, Diagnostic, and
Treatment benefit
• MVPAP

• Reduced staff compliance
• education
• busy clinic
• missed opportunities
• Reduced patient compliance
• education
• cost
• time

STRENGTHS

WEAKNESSES

THREATS

OPPORTUNITIES

• Barriers to compliance:
• low staff compliance
• no accountability
• no attempts to f/u or remind
patients
• text reminders
• phone calls
• e-mails
• letters
• no checks & balances
• flags in EHR
• weekly reports
• meetings to educate
staffon the need for
patient education and f/u
appointment scheduling

• All clinic staff reducing missed
opportunities
• Use of EHR to set flags/alerts
when chart brought up
• MAs education
• providing education materials
• reviewing EHR for vaccines
• scheduling subsequent doses
ahead of time and providing
with reminder cards
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Appendix D:
Cost Analysis

Step One: COSTS
◦Calculate your costs:
-Time spent: ~200 hours (~$40/hr) = $8000
-researching/writing/presenting ~40 = $1600
-at the clinic (phone calls, education) ~130 = $ 5200
-at organizational meetings ~15 = $600
-with staff education ~15 = $600
Step Two: BENEFITS
While improving HPV vaccination compliance rates is the goal, the organization would
benefit from an increased number of vaccinations as a result of increased patient participation in
the VFC program. Current estimated cost of the Gardasil® 3-dose series is ~$263 per dose
(=$789 for full 3-dose series). Current estimated cost with use of VFC is $0 for each and all 3
doses. Individuals who are 19-20 years of age and qualify for Medicaid also pay $0 for each and
all 3 doses. In addition the MVPAP program can also provide the vaccination(s) at no cost
dependent if individual fulfills criteria. If the patient does not fall within the above programs, the
clinic charges $175 per dose (=$525 for full 3-dose series). Many clients are without insurance
and will therefore make scheduled payments to cover costs. All individuals will be charged on a
sliding scale (dependent on income and insurance) $0-10 Administration Fee, which covers time,
supplies, and administration.
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Step Three: NET BENEFITS
The goal is to increase vaccinations by 10% or approximately 237 individuals (including
both 2nd and 3rd dose individuals). At a rate $175 per dose ($525 for all 3 doses), benefits would
equal $41,475 - $124,425 for an approximate 10% increase. The net benefit would be ~ $33,475
- $116,425. These figures are dependent on whether or not the individual partakes within the
VFC, Medicaid, MVPAP, private/public insurance, or pays out-of-pocket.
Step Four: QUALITATIVE BENEFITS
The qualitative benefits from this project would include quality of life (i.e. reduced risk
of cancers and other related infections, longer life expectancy) for patients, and improved HPV
compliance rates for our clinic in particular. As this organization runs 13 clinics, it would be
wonderful to see if implementation of follow-up phone calls at one clinic was effective enough
to spread to all 13 clinics, thereby improving the organization’s overall HPV vaccination
compliance rate.
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Appendix E:
Stakeholder Analysis
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Appendix F:
PDSA Ramps
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Appendix G:
Results
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Appendix G:
Comparison Rates

2nd & 3rd Dose Comparison Rates
40%
47.70%

3rd dose

31.60%
7%
50.30%
61.50%

2nd dose

26.70%
7%
0%
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Appendix H:
Timeline

